Collaboration and License Agreements - Additional Information (Details)
|
|
1 Months Ended |
3 Months Ended |
12 Months Ended |
Oct. 01, 2018
USD ($)
$ / shares
shares
|
Dec. 31, 2018
USD ($)
|
Aug. 31, 2018
USD ($)
Program
|
Jul. 31, 2018
Program
|
Aug. 31, 2017
USD ($)
Program
|
Jun. 30, 2016
USD ($)
|
Mar. 31, 2015
USD ($)
|
Sep. 30, 2014
USD ($)
|
May 31, 2014
USD ($)
|
Dec. 31, 2018
USD ($)
|
Sep. 30, 2018
USD ($)
|
Jul. 31, 2018
USD ($)
|
Jun. 30, 2018
USD ($)
|
Mar. 31, 2018
USD ($)
|
Dec. 31, 2017
USD ($)
|
Sep. 30, 2017
USD ($)
|
Jun. 30, 2017
USD ($)
|
Mar. 31, 2017
USD ($)
|
Dec. 31, 2018
USD ($)
shares
|
Dec. 31, 2017
USD ($)
|
Dec. 31, 2016
USD ($)
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
$ 2,489,000
|
|
|
|
|
|
|
|
$ 2,489,000
|
|
|
|
|
$ 1,624,000
|
|
|
|
$ 2,489,000
|
$ 1,624,000
|
|
Total revenue |
|
|
|
|
|
|
|
|
|
19,086,000
|
$ 7,836,000
|
|
$ 5,704,000
|
$ 5,793,000
|
4,040,000
|
$ 17,499,000
|
$ 15,357,000
|
$ 14,845,000
|
38,419,000
|
51,741,000
|
$ 59,731,000
|
Proceeds from issuances of redeemable convertible preferred stock, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
84,739,000
|
0
|
$ 0
|
Contingent payments of embedded derivative and related liability |
|
100,000
|
|
|
|
|
|
|
|
100,000
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
The Leukemia & Lymphoma Society, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research development and commercialization agreement termination period |
|
|
12 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research development and commercialization agreement termination description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The LLS Agreement terminates upon the earlier of (a) fulfillment of all payment obligations by both parties or (b) 12 years after the effective date. LLS may terminate the LLS Agreement at any time with 60 days’ prior written notice. Either the Company or LLS has the right to terminate the LLS Agreement based on the other party’s uncured material breach
|
|
|
Common Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock, shares | shares |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,667,000
|
|
|
Series E Redeemable Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuances of redeemable convertible preferred stock, net of issuance costs |
|
|
|
|
|
|
|
|
|
|
|
$ 85,400,000
|
|
|
|
|
|
|
|
|
|
2014 Celgene Agreement | Celgene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Up-front, nonrefundable payment received |
|
|
|
|
|
|
|
$ 83,100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Contingent payment received |
|
|
|
|
|
|
$ 15,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment received |
|
|
|
|
|
$ 25,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional milestone payment received |
|
|
|
|
|
10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone revenue recognized |
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognized of deferred revenue over the entire period |
|
|
|
|
$ 8,200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2017 Celgene Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
600,000
|
|
|
|
|
|
|
|
600,000
|
|
|
|
|
800,000
|
|
|
|
$ 600,000
|
800,000
|
|
2017 Celgene Agreement | Celgene |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional milestone payment received |
|
10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone revenue recognized |
|
10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of programs advancing through preclinical development | Program |
|
|
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option fee payment received |
|
|
|
|
$ 12,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second option fee payment received |
|
|
|
|
$ 12,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of investigational new drug program | Program |
|
|
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognized of deferred revenue over the entire period |
|
11,400,000
|
|
|
$ 12,500,000
|
|
|
|
|
11,400,000
|
|
|
|
|
18,000,000
|
|
|
|
11,400,000
|
18,000,000
|
|
2017 Celgene Agreement | Celgene | Licensed Products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum aggregate milestone and option fee payments eligible to receive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
295,000,000
|
|
|
2017 Celgene Agreement | Celgene | Other Licensed Products |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum aggregate milestone and option fee payments eligible to receive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
393,700,000
|
|
|
2018 Celgene Master Services Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other revenue-related parties |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,500,000
|
|
|
2018 Merck Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognized of deferred revenue over the entire period |
|
53,000,000
|
|
|
|
|
|
|
|
53,000,000
|
|
|
|
|
|
|
|
|
53,000,000
|
|
|
Accounts receivable |
|
900,000
|
|
|
|
|
|
|
|
900,000
|
|
|
|
|
|
|
|
|
900,000
|
|
|
2018 Merck Agreement | Merck |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognized of deferred revenue over the entire period |
|
|
$ 55,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of research programs | Program |
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Upfront payment received |
|
|
$ 60,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of target programs | Program |
|
|
2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Upfront payment received allocated to estimated significant incremental discount |
|
|
$ 4,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue recognition aggregate milestone payments eligible to receive |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,600,000,000
|
|
|
Milestone method revenue recognition description |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
If one or more products from each of the target programs are developed for non-oncology or a single indication, the Company will be eligible for reduced aggregate milestone payments. In addition, the Company is eligible to receive tiered royalties ranging from mid-single digit to low teen percentages on the worldwide sales of any commercial products that may result from the collaboration.
|
|
|
2018 Merck Agreement | Merck | Common Stock | Private Placement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock, shares | shares |
666,666
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share issue price per share | $ / shares |
$ 15.00
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018 Merck Agreement | Merck | Series E Redeemable Convertible Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock, shares | shares |
74,794,315
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share issue price per share | $ / shares |
$ 0.2674
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuances of redeemable convertible preferred stock, net of issuance costs |
$ 20,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2018 Merck Agreement | Merck | Collaboration Revenue, Amortization of Up-front Payment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 7,000,000
|
|
|
2018 Merck Agreement | Merck | Collaboration Revenue, Research and Development Services |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,500,000
|
|
|
Collaboration Agreement | EMD Serono |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Up-front, nonrefundable and non-creditable payment received |
|
|
|
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
MDA Agreement | EMD Serono |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recognized of deferred revenue over the entire period |
|
1,700,000
|
|
|
|
|
|
|
|
1,700,000
|
|
|
|
|
5,900,000
|
|
|
|
$ 1,700,000
|
5,900,000
|
|
Up-front, nonrefundable and non-creditable payment received |
|
|
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Estimated period of recognizing revenues from up-front payments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2014-06
|
|
|
Maximum amount eligible to receive for each product developed |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 52,500,000
|
|
|
Accounts receivable |
|
900,000
|
|
|
|
|
|
|
|
900,000
|
|
|
|
|
$ 800,000
|
|
|
|
900,000
|
$ 800,000
|
|
Supply Agreement |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
49,000,000,000
|
|
|
|
|
|
|
|
49,000,000,000
|
|
|
|
|
|
|
|
|
49,000,000,000
|
|
|
Other revenue-related parties |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,500,000
|
|
|
Research Development and Commercialization Agreement | The Leukemia & Lymphoma Society, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maximum contribution in clinical development |
|
|
6,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Initial milestone payment |
|
|
500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total milestone payments received |
|
|
1,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment received against other income (expense) |
|
|
900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment received remaining other current liabilities |
|
$ 100,000
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
Maximum aggregate payment |
|
|
$ 19,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|